Cardiomyopathy Trial, Recruiting NCT07054073 Sponsor: Christopher Kramer Condition: Cardiomyopathy
Back to Cardiomyopathy

Cardiomyopathy Trial, Recruiting

NCT07054073
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You were part of the original HCMR study group
  • You are between 18 and 65 years old (male or female)
  • If you have the obstructive type of HCM (thickened heart muscle that blocks blood flow): Your body weight relative to height (BMI) is under 35, and tests show that blood flow out of your heart is significantly restricted, either at rest or after a specific breathing test called the Valsalva maneuver, and you have mild-to-moderate symptoms affecting daily activity
  • If you have the non-obstructive type of HCM (thickened heart muscle without a major blockage): Your BMI is under 40, blood flow tests show no significant blockage, a specific heart stress marker in your blood (NT-proBNP) is elevated above a certain level, and your heart's pumping strength is at or above 55%

Who may not be able to join:

  • You have a history of an irregular heart rhythm called atrial fibrillation or flutter that comes and goes
  • You have had atrial fibrillation requiring treatments such as electric shock to reset your heart rhythm, a catheter ablation procedure, or heart rhythm medications within the past 6 months (though this may not apply if your atrial fibrillation has been well-controlled with blood thinners for more than 6 months — confirm with trial site)
  • You have fainted or had a dangerous fast heart rhythm during exercise in the past 6 months
  • You are currently pregnant, due to potential risks from the dye (gadolinium) used in MRI scans
  • You have a pacemaker that your heart fully depends on to beat, as this prevents you from safely having an MRI scan

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Christopher Kramer, MD, University of Virginia

Phone: 434-924-9553

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Christopher Kramer
Registry
ClinicalTrials.gov
Start date
30 March 2026
Est. completion
1 March 2027

Where this trial is recruiting

🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Change in % LGE mass

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov